Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Friday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of EGRX opened at $0.71 on Friday. The company has a 50-day simple moving average of $1.21 and a 200-day simple moving average of $3.40. Eagle Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $6.81.

Institutional Trading of Eagle Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. AIGH Capital Management LLC lifted its position in Eagle Pharmaceuticals by 2.1% in the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after purchasing an additional 25,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after acquiring an additional 2,630 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $971,000. RBF Capital LLC increased its stake in Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Eagle Pharmaceuticals in the third quarter worth about $453,000. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.